Mr. Schultz was the Chief Executive Officer and a director of Teva Pharmaceutical Industries Ltd. from November 2017 to January 2023. From 2015 to October 2017, Mr. Schultz served as the President and Chief Executive Officer of H. Lundbeck A/S. Prior to joining Lundbeck, Mr. Schultz worked for nearly three decades at Novo Nordisk, where he served in a number of leadership roles, including Chief Operating Officer, Vice President in Product Supply and Director of Product Planning and Customer Services for the Diabetes Care Division, and he played a major role in modernizing the company s large scale biologic production and leading expansion into the US and Chinese markets. In addition to his time at Novo Nordisk, Mr. Schultz has held positions at McKinsey and Andersen Consulting. In these roles, he developed a unique global perspective on the healthcare and pharmaceutical industries, expanded his deep financial acumen, demonstrated a commitment to strong compliance principles and enforcement and oversaw business operations and teams across Europe and North America and the Middle East. He has served as a director, Chair of the Board and a member of the Audit Committee of Azelis Holding S.A., a specialty chemical supplier, since June 2024. He has served as the Chair of the Board of Scandinavian Airlines Systems AB since September 2024 and of Bespak Ltd., a pharmaceutical products and supplies manufacturer, since April 2024. He previously served as a director of International Flavors & Fragrances, Inc., a global leader in flavors, fragrances, food ingredients and health and biosciences, from February 2021 through March 2023. He holds a master s degree in Economics from the University of Copenhagen. We believe Mr. Schultz is qualified to serve on our Board of Directors because of his deep experience in the pharmaceutical industry, including various leadership roles across major companies.